Highly metastatic and chemotherapy-resistant properties of malignant melanomas stand as challenging barriers to successful treatment, yet the mechanisms responsible for their aggressive characteristics are not fully defined. We show that a distinct population expressing CD133 (Prominin-1), which is highly enriched after administration of a chemotherapeutic drug, dacarbazine, has enhanced metastatic potential in vivo. 
Introduction
Malignant melanoma is highly metastatic and notoriously resistant to conventional therapies, posing a challenging therapeutic obstacle attributed to tumor population heterogeneity (1) (2) .
Numerous clinical approaches have been suggested, including chemotherapy and immunological therapies, for treating melanoma (3-4), but they have yet to produce a remarkable therapeutic effect. Response rates to dacarbazine, the most widely used agent for melanoma treatment, are significantly low at 10~25% (5) and its administration can rather enhance metastatic potential as well as tumorigenic properties in vivo (6) . Although several molecular mechanisms for drug resistance have been evaluated, such as increased DNA repair and cytokine expression in melanoma, resistance to chemotherapy and an inducedaggressive metastatic phenotype remain as major challenges for melanoma treatment.
The existence of a rare tumor-initiating subpopulation that exhibits resistance to conventional cancer therapies has been proposed (7) (8) . Recent studies in melanoma have addressed a possible mechanism for tumor chemo-resistance, identifying drug transporter ABCB5 as a critical mediator of tumor initiation as well as chemo-resistance (9) (10) .
Although the rarity of tumorigenic cells identified by specific surface markers has been challenged, especially in the context of melanoma (11) (12) (13) , it remains unanswered whether distinct subpopulations are more responsible for chemo-resistance than a heterogeneous population. Also, the molecular features that characterize chemoresistant cells require further investigation.
Metastasis occurs in an organ-specific and highly organized manner. Certain tumors are prone to metastasize to preferred sites by diverse determinants, such as intrinsic properties of tumor cells and circulation patterns (14) . microenvironment at metastatic sites can modulate metastatic potential (15) . The molecular basis of organ-specific metastasis is poorly understood, but local microenvironmental components of metastatic sites can create a conducive niche for attracting tumor cells to favorable organs (16) . Chemokine-mediated mechanisms also govern the pattern of metastasis to specific target organs, in that the local expression of chemoattractants may guide chemokine receptor-expressing tumor cells to specific target organs (17) (18) (19) . In addition to using blood vessels, solid tumors can also utilize the lymphatic vasculature to disseminate tumor cells to distant sites (20) (21) (22) . In malignant melanoma, lymphatic vessels represent the major route of metastatic dissemination (23) . Lymph node (LN) metastasis is the first step of tumor dissemination for a variety of human cancers including melanoma. Although the degree of LN metastasis has long been one of the criteria for determining the prognosis of human cancers, the molecular mechanisms of lymphatic metastasis are poorly understood (24) . Whether the LNs encourage tumor cell dissemination for further systemic metastasis also remains to be determined. However, the LNs may provide a supportive environment for tumor metastasis by increasing the metastatic propensity of tumor cells (15) . Regulation of lymphatic vessel growth also affects pulmonary metastasis, beyond regional LN metastasis, in mouse models of some cancers (25) (26) . Vascular growth factor-C (VEGF-C), a lymphangiogenic factor, directly induces lung lymphangiogenesis which promotes intralymphatic spread in the lungs (27) .
Our goal was not to wade into the controversy about the presence of melanoma stem cells to seed cancer growth but rather to determine underlying mechanisms mediating active metastasis of chemoresistant melanoma cells to specific target organs. Here, we demonstrate that a lymphatic microenvironment at metastatic sites promotes the recruitment of disseminating tumor cells with a particular affinity for CD133-positive tumor cells, which are 
Drug treatment
Seven days after tumor implantation, drug treatment was started. For dacarbazine treatment, a treatment cycle consisted of an intraperitoneal injection of darcabazine (25 mg/kg, SigmaAldrich) after an epifocal application of dinitrochlorobenzene (dissolved in mixture of acetone and olive oil-4:1) on the tumor. For the first cycle, the tumors were treated with 2% dinitrochlorobenzene, whereas for the following cycles 1% dinitrochlorobenzene was used.
Cycles were repeated every four days. As a control, equal volumes of vehicle were administered in the same manner. To block CXCR4, 1.25 mg/kg of AMD3100 (Sigma- Aldrich) was subcutaneously administered every other day for 2 weeks. To block VEGF-C/D, 1x10 9 pfu of Ad-sVEGFR-3 or Ad-βgal was intravenously delivered starting from three days after tumor implantation once a week for 3 weeks.
Statistical analysis
Values are presented as mean ± standard deviation (SD). Significant differences between means were determined by unpaired Student t-test or analysis of variance with one-way ANOVA followed by the Student-Newman-Keuls test. Statistical significance was set at
P<0.05.
on within the tumor population depleted of hematopoietic and endothelial progenitors relative to vehicle-treated mice, showing high resistance of the CD133-expressing subset to the chemotherapeutic drug ( Fig. 1A and B) .
We 
Lymphatic vessels regulate metastasis of CD133 + tumor cells in vivo
Based on the aforementioned findings, we questioned whether the modulation of lymphatic growth could regulate CD133 + tumor cell metastasis in vivo. To answer this question, we reduced lymphatic growth through the blockade of VEGF-C/VEGFR-3 signaling by adenoviral delivery of soluble VEGFR-3 (Ad-sVEGFR-3) (30). Conversely, K14-VEGF-C transgenic mice (28), which have dense and enlarged lymphatic vessels in the skin dermis, were used to see the effects of increased lymphatic growth in tumor metastasis. As we expected, Ad-sVEGFR-3 delivery reduced both lymphatic density and blood vessel density in tumor, compared to adenoviral βgal delivery (Ad-βgal); whereas melanoma-bearing K14-VEGF-C transgenic mice showed a profound increase in lymphatic density in tumor, 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research 15 compared to wild-type (WT) littermate mice ( Supplementary Fig. S4C-F) . Growth of lymphatic vessels rather than blood vessels was remarkably decreased in ALNs after AdsVEGFR-3 treatment and, in an adverse manner, K14-VEGF-C transgenic mice showed a significant increase in lymphatic density in ALNs (Fig. 3A and B and Supplementary Fig.   S4G ). Both Ad-sVEGFR-3 treatment and K14-VEGF-C transgenic phenotype had no impact on either tumor growth or percentage of CD133 + cell population in tumor ( Supplementary   Fig. S4A and B) . Importantly, CD133 + /MelanA + cell metastasis to ALNs was 81% less after administration of Ad-sVEGFR-3 compared to Ad-βgal, but it was increased ~2.4-fold in K14-VEGF-C transgenic mice compared with wild-type mice with melanoma ( Fig. 3C-E) .
Moreover, compared to Ad-βgal, the number of tumor colonies was 85% less in AdsVEGFR-3-treated mice while pulmonary metastasis increased ~2.1-fold in the lungs of K14-VEGF-C transgenic mice (Fig. 3F) . Interestingly, quantitative RT-PCR of RNA isolated from 
Copyright © 2010 American Association for Cancer Research 16 reported in some cancers (18), we next investigated whether the SDF-1/CXCR4 axis is involved in the interaction between CD133 + cells and lymphatic vessels, and contributes to forming a lymphatic metastatic niche for guiding CD133 + tumor cell metastasis. For this purpose, we first examined the expression of SDF-1 on lymphatic vessels in metastatic tissues. Immunofluorescence staining showed strong expression of SDF-1 on lymphatic vessels in the metastasized ALNs of tumor-implanted mice, whereas its expression was weak and undetectable in lymphatic vessels of normal ALNs of mice without tumor implantation (Fig. 4A) . Strong SDF-1 expression was also observed in lymphatic vessels of either primary tumor or metastasized lungs, but not in other tissues of the melanoma-bearing mice ( Supplementary Fig. S6A ). In agreement with these findings, SDF-1 and VEGFR-3 mRNA expression levels were, respectively, ~6.6-and ~3.8-fold higher in the ALNs and were ~3.8-and ~2.2-fold higher in lung tissues of melanoma-bearing mice compared to normal mice ( Supplementary Fig. S6B ). However, their expression levels were not significantly changed in other organs such as liver, spleen and testis in which metastasis was infrequently observed after tumor implantation ( Supplementary Fig. S6B and data not shown). These findings led us to assess the expression of CXCR4, a specific receptor for SDF-1, particularly in CD133 + melanoma cells. Flow cytometric analysis showed that a distinct population of CD133 + cells (57.9%) expressed CXCR4 in tumor (Fig. 4B) . Furthermore, immunofluorescence co-staining confirmed that a certain set of CD133 + /MelanA + cells in the ALNs express CXCR4 (Fig. 4C ).
Based on these findings, we hypothesized that the CXCR4- (Fig. 4F-H) , even though both groups showed similar extents of tumor growth ( Fig. 4D and E) . These results indicate that SDF-1 mediates CD133 + cell metastasis toward a lymphatic metastatic niche in target organs.
Blockade of CXCR4 signaling reduces physical association of CD133 + cells to LECs
To demonstrate whether CXCR4 signaling is a responsible mediator for physical association between CD133 + tumor cells and LECs, freshly isolated CD133 + and CD133 -cells from tumor were labeled with a green fluorescent dye CFDA-SE and co-cultured with LECs in Matrigel for 24 hr. We observed that, compared to CD133 -cells, CD133 + tumor cells associated more closely with LECs ( Fig. 5A and B) . Importantly, blockade of CXCR4 with anti-CXCR4 blocking antibody significantly impaired the association between CD133 + tumor cells and LECs by 25%, whereas the association between CD133 -tumor cells and LECs was only slightly affected after CXCR4 blockade ( Fig. 5A and B) .
Blockade of CXCR4 signaling suppresses tumor metastasis to the ALNs and lungs
To confirm that CXCR4 signaling is responsible for melanoma metastasis, especially of the chemoresistant CD133 + cells, we administered a CXCR4 inhibitor AMD3100 and a cytotoxic chemotherapeutic agent dacarbazine one week after melanoma implantation. Blocking CXCR4 signaling with AMD3100 did not significantly affect either tumor growth or percentage of CD133 + cell population in tumor (Fig. 6A-C) , but it significantly reduced CD133 + tumor cell metastasis to ALNs and pulmonary metastasis, compared to the vehicle (Fig. 6D-G reduced by AMD3100 treatment (Fig. 6E) . In comparison, dacarbazine alone or combined treatment of AMD3100 plus dacarbazine increased the percentage of CD133 + cell population in tumor by ~5.8-fold and ~5.7-fold, respectively, compared to the vehicle (Fig. 6C) . In terms of metastasis, as we expected, dacarbazine treatment alone could not block metastasis to the ALNs and lungs although it reduced tumor growth by 55% (Fig. 6A and B) . However, importantly, combined treatment of AMD3100 plus dacarbazine showed a significant reduction in tumor metastasis either to ALNs by 62% or to lungs by 49% and also induced a decrease in the number of tumor cells surrounding lymphatic vessels in the lungs (Fig. 6D-G) .
Together, our results confirm that CXCR4 signaling is a crucial pathway in regulating metastatic activity of chemoresistant CD133 + tumor cells toward a lymphatic niche in target metastatic organs (Supplementary Fig. S7 ). Therefore, the blockade of CXCR4 signaling plus dacarbazine administration suppresses the highly metastatic phenotype of melanoma, which remains as a significant problem with dacarbazine treatment alone. 
Discussion
The underlying mechanisms of highly metastatic and chemoresistant characteristics of malignant melanomas are still poorly understood for the development of an effective treatment. Our study identifies a distinct population expressing CD133 (Prominin-1) that is highly enriched after repeated exposure of a chemotherapeutic drug, which may lead to the selection of certain tumor subsets. Importantly, our data demonstrate that lymphatic microenvironments actively regulate metastasis of CD133 + cells with high metastatic potential by a specific signaling pathway in vivo ( Supplementary Fig. S7 ).
CD133
+ tumor cells represent the cellular population that confers radio-and chemoresistance and could be the source of tumor recurrence after therapeutic treatments (7, 31) .
Our study confirmed that, in vivo, the CD133 + subpopulation is highly enriched in a melanoma model after administration of dacarbazine, which is generally considered to be the In conclusion, our study demonstrates the role of a lymphatic microenvironment at preferred metastatic sites in guiding metastasis of a distinct tumor subset expressing CD133 that is enriched after dacarbazine treatment. Here, the SDF-1/CXCR4 axis is essential for the functionality of the lymphatic metastatic niche that attracts CXCR4-expressing tumor cells.
We unraveled the role of lymphatic vessels as a novel source of SDF-1, which promotes the metastasis of CXCR4-expressing CD133 + cells (Supplementary Fig. S7 ). Importantly, the blockade of CXCR4 signaling coupled with dacarbazine treatment impaired LN and pulmonary metastases as well as tumor growth. Thus, our findings suggest that targeting the SDF-1/CXCR4 axis, a key regulator of the lymphatic niche, will lead to a novel 
